Bioxyne Limited (AU:BXN)
ASX:BXN
Want to see AU:BXN full AI Analyst Report?
BXN Stock Chart & Stats
AU$0.04
<AU$0.01(4.17%)
At close: 4:00 PM EST
AU$0.04
<AU$0.01(4.17%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.08
Previous CloseN/A
Volume631.90K
Average Volume (3M)4.35M
Market Cap
AU$136.24M
Enterprise ValueAU$136.06M
Total Cash (Recent Filing)AU$7.60M
Total Debt (Recent Filing)AU$7.43M
Price to Earnings (P/E)3.2
Beta1.24
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,270,594,200
10 Day Avg. Volume2,483,521
30 Day Avg. Volume4,348,514
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)7.54
Price to Sales (P/S)2.90
P/FCF Ratio22.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained 77% top-line growth indicates strong product-market fit in medical cannabis and expanding commercial reach. Durable revenue expansion supports scaling of manufacturing and distribution contracts, improves bargaining with partners, and underpins multi-quarter investment in capacity and R&D.
Profitability ImprovementDouble-digit EBIT and net margins reflect persistent operational efficiency and cost control in manufacturing and distribution. Higher margins increase internal funding capacity for product development and market expansion, reducing reliance on external capital over a multi-quarter horizon.
Cash GenerationA major FCF turnaround with strong cash conversion metrics signals improved earnings quality and working-capital management. Reliable cash generation creates durable financial flexibility to fund GMP capacity, regulatory compliance, or selective M&A without immediate equity dilution.
Bears Say
Moderate Gross MarginA sub-35% gross margin limits the buffer against input cost inflation, pricing pressure, or distributor discounts. Structural margin constraints can cap operating leverage as the company scales, requiring continuous improvement in cultivation yield, procurement or higher-margin product mix to sustain net profitability.
Regulatory DependenceRevenue and market access hinge on regulatory approvals and product listings; these are structural risks that can delay launches, limit distribution channels, or change reimbursement. Over months, regulatory setbacks or slower listings can materially impede growth and commercial plans.
Limited Scale / Small TeamA very small headcount signals limited internal capacity for simultaneous cultivation expansion, compliance, sales, and product development. Execution risk rises as the company scales; dependence on a compact team or key individuals can slow commercialization and increase operational bottlenecks.
Bioxyne Limited News
BXN FAQ
What was Bioxyne Limited’s price range in the past 12 months?
Bioxyne Limited lowest share price was AU$0.02 and its highest was AU$0.08 in the past 12 months.
What is Bioxyne Limited’s market cap?
Bioxyne Limited’s market cap is AU$136.24M.
When is Bioxyne Limited’s upcoming earnings report date?
Bioxyne Limited’s upcoming earnings report date is Aug 28, 2026 which is in 120 days.
How were Bioxyne Limited’s earnings last quarter?
Bioxyne Limited released its earnings results on Feb 25, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Bioxyne Limited overvalued?
According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued.
Does Bioxyne Limited pay dividends?
Bioxyne Limited does not currently pay dividends.
What is Bioxyne Limited’s EPS estimate?
Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioxyne Limited have?
Bioxyne Limited has 2,270,594,200 shares outstanding.
What happened to Bioxyne Limited’s price movement after its last earnings report?
Bioxyne Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.385%.
Which hedge fund is a major shareholder of Bioxyne Limited?
Currently, no hedge funds are holding shares in AU:BXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioxyne Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BXN Sentiment 83%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$90.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
56.29%
Trailing 12-Months
Asset Growth
131.94%
Trailing 12-Months
Company Description
Bioxyne Limited
Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.
Technical Analysis
Wellnex Life Ltd
―
EVE Health Group Limited
―
Holista Colltech Limited
―
Clover Corporation Limited
―
Maggie Beer Holdings Ltd.
―
Options Prices
Currently, No data available
---